These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

876 related articles for article (PubMed ID: 34754219)

  • 21. Combined Effect of
    Chen J; Wu Y; He Y; Feng X; Ren Y; Liu S
    Front Pediatr; 2022; 10():846411. PubMed ID: 35386257
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations.
    Encalada Ventura MA; van Wanrooy MJ; Span LF; Rodgers MG; van den Heuvel ER; Uges DR; van der Werf TS; Kosterink JG; Alffenaar JW
    Antimicrob Agents Chemother; 2016 May; 60(5):2727-31. PubMed ID: 26883707
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of proton pump inhibitors in children.
    Litalien C; Théorêt Y; Faure C
    Clin Pharmacokinet; 2005; 44(5):441-66. PubMed ID: 15871633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies.
    Furuta T; Shirai N; Sugimoto M; Nakamura A; Hishida A; Ishizaki T
    Drug Metab Pharmacokinet; 2005 Jun; 20(3):153-67. PubMed ID: 15988117
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenetic Expression of CYP2C19 in a Pediatric Population.
    Pierre-François MJD; Gagné V; Brukner I; Krajinovic M
    J Pers Med; 2022 Aug; 12(9):. PubMed ID: 36143168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Voriconazole-induced visual abnormality based on drug interaction between voriconazole and esomeprazole: A case report.
    Jiang Z; Li J; Zhao C; Chen J
    Int J Clin Pharmacol Ther; 2023 Oct; 61(10):460-465. PubMed ID: 37548457
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Therapeutic drug monitoring of voriconazole and CYP2C19 phenotype for dose optimization in paediatric patients.
    Hu L; Huang Q; Huang S; Feng Z
    Eur J Clin Pharmacol; 2023 Sep; 79(9):1271-1278. PubMed ID: 37458772
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical significance of the cytochrome P450 2C19 genetic polymorphism.
    Desta Z; Zhao X; Shin JG; Flockhart DA
    Clin Pharmacokinet; 2002; 41(12):913-58. PubMed ID: 12222994
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Obesity on Voriconazole Pharmacokinetics among Pediatric Hematopoietic Cell Transplant Recipients.
    Takahashi T; Smith AR; Jacobson PA; Fisher J; Rubin NT; Kirstein MN
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32988816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacogenomics of proton pump inhibitors.
    Furuta T; Shirai N; Sugimoto M; Ohashi K; Ishizaki T
    Pharmacogenomics; 2004 Mar; 5(2):181-202. PubMed ID: 15016609
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impact of proton pump inhibitors on the pharmacokinetics of voriconazole in vitro and in vivo.
    Yan M; Wu ZF; Tang D; Wang F; Xiao YW; Xu P; Zhang BK; Liu YP; Xiang DX; Banh HL
    Biomed Pharmacother; 2018 Dec; 108():60-64. PubMed ID: 30216801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of C-reactive protein on the pharmacokinetics of voriconazole in relation to the
    Ling J; Yang X; Dong L; Jiang Y; Zou S; Hu N
    Front Pharmacol; 2024; 15():1455721. PubMed ID: 39228522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
    Frelinger AL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Brooks JK; Bhatt DL; Michelson AD
    J Am Coll Cardiol; 2012 Apr; 59(14):1304-11. PubMed ID: 22464259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Prospective Study on the Usefulness of Initial Voriconazole Dose Adjustment Based on CYP2C19 Gene Polymorphism Analysis.
    Tanaka R; Fujioka T; Suzuki Y; Iwao M; Itoh H
    Chemotherapy; 2020; 65(3-4):59-64. PubMed ID: 32877905
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose optimisation of voriconazole with therapeutic drug monitoring in children: a single-centre experience in China.
    Liu L; Zhou X; Wu T; Jiang H; Yang S; Zhang Y
    Int J Antimicrob Agents; 2017 Apr; 49(4):483-487. PubMed ID: 28159657
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The influence of CYP2C19 polymorphisms on voriconazole trough concentrations: Systematic review and meta-analysis.
    Zhang Y; Hou K; Liu F; Luo X; He S; Hu L; Yang C; Huang L; Feng Y
    Mycoses; 2021 Aug; 64(8):860-873. PubMed ID: 33896064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study.
    Blanco-Dorado S; Maroñas O; Latorre-Pellicer A; Rodríguez Jato MT; López-Vizcaíno A; Gómez Márquez A; Bardán García B; Belles Medall D; Barbeito Castiñeiras G; Pérez Del Molino Bernal ML; Campos-Toimil M; Otero Espinar F; Blanco Hortas A; Durán Piñeiro G; Zarra Ferro I; Carracedo Á; Lamas MJ; Fernández-Ferreiro A
    Pharmacotherapy; 2020 Jan; 40(1):17-25. PubMed ID: 31782536
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19.
    Zvyaga T; Chang SY; Chen C; Yang Z; Vuppugalla R; Hurley J; Thorndike D; Wagner A; Chimalakonda A; Rodrigues AD
    Drug Metab Dispos; 2012 Sep; 40(9):1698-711. PubMed ID: 22648560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Influence of CYP2C19 Genotypes on the Occurrence of Adverse Drug Reactions of Voriconazole among Hematological Patients after Allo-HSCT.
    Sienkiewicz B; Urbaniak-Kujda D; Dybko J; Dryś A; Hurkacz M; Wróbel T; Wiela-Hojeńska A
    Pathol Oncol Res; 2018 Jul; 24(3):541-545. PubMed ID: 28685218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CYP2C19 polymorphism influences Helicobacter pylori eradication.
    Kuo CH; Lu CY; Shih HY; Liu CJ; Wu MC; Hu HM; Hsu WH; Yu FJ; Wu DC; Kuo FC
    World J Gastroenterol; 2014 Nov; 20(43):16029-36. PubMed ID: 25473155
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.